GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions
What's Next for Alzheimer's Treatment? Some Scientists Are Betting on GLP-1 Drugs
Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon confirm that.
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, addiction, heart disease, and gastrointestinal problems, among others.
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits,
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
Benefits and risks of GLP-1 drugs and criteria for dementia diagnosis
In today’s health headlines, the 175 health benefits and risks of taking GLP-1 drugs. Also, many older adults don’t realize they meet the criteria for a dementia diagnosis. Finally, what are the brain effects of short video watching on TikTok and reels?
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY, rose 3% and 2.3% on Tuesday, respectively, after results from a study showed that GLP-1 drugs cut the risk of several heart conditions,
Weight Loss Medications Linked To Lower Dementia And Heart Risk: Study
GLP-1 medications like Ozempic, Wegovy, and Mounjaro are linked to reduced risks of dementia, heart failure, and severe infections, according to a study involving over 2 million patients. However, these weight-loss and diabetes drugs also pose risks,
Renal & Urology News17h
GLP-1 Receptor Agonists May Have Broader Range of Benefits, Risks
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
Medscape1d
GLP-1 Benefits, Risks Detailed in ‘Atlas’ Mapping Outcomes
The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...
News Medical on MSN4d
Researchers create an atlas of health associations for GLP-1 receptor agonists
Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
HealthDay on MSN2d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the ...
Healio10d
GLP-1 receptor agonists tied to similar thyroid cancer risk as DPP-IV inhibitors
Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...
clinicaladvisor.com1d
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders.
Pharm Exec3d
Novel GLP-1 Receptor Agonist Demonstrates Promising Results Treating Patients with Obesity
Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...
Allurion Technologies to initiate GLP-1 study optimizing for muscle mass
Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Program with GLP-1 ...